phosphorylcholine has been researched along with Coronary Restenosis in 23 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial was a randomized controlled study of zotarolimus-eluting, phosphorylcholine-coated, cobalt-alloy stents for the treatment of de novo coronary lesions compared with using PES for the same treatment." | 9.14 | Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. ( Ako, J; Fitzgerald, PJ; Hasegawa, T; Honda, Y; Kandzari, DE; Leon, MB; Miyazawa, A; Sakurai, R; Tsujino, I; Waseda, K; Yock, PG, 2009) |
| "The ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial was a randomized controlled study of zotarolimus-eluting, phosphorylcholine-coated, cobalt-alloy stents for the treatment of de novo coronary lesions compared with using PES for the same treatment." | 5.14 | Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. ( Ako, J; Fitzgerald, PJ; Hasegawa, T; Honda, Y; Kandzari, DE; Leon, MB; Miyazawa, A; Sakurai, R; Tsujino, I; Waseda, K; Yock, PG, 2009) |
| "Patients (n =1,197) treated for single coronary artery stenosis were enrolled in a prospective, randomized, double-blind study and randomly assigned to receive the Endeavor zotarolimus-eluting phosphorylcholine polymer-coated stent (n= 598) or the same bare metal stent but without the drug or the polymer coating (n=599)." | 5.12 | Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. ( Bonan, R; Fajadet, J; Fitzgerald, PJ; Kuck, KH; Kuntz, RE; Laarman, GJ; Münzel, T; Ormiston, J; Popma, JJ; Wijns, W, 2007) |
| "Zotarolimus is a recently developed pharmacologic agent with both antiproliferative and anti-inflammatory properties." | 2.43 | Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. ( Kandzari, DE; Leon, MB, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 20 (86.96) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Waseda, K | 1 |
| Miyazawa, A | 1 |
| Ako, J | 1 |
| Hasegawa, T | 1 |
| Tsujino, I | 1 |
| Sakurai, R | 2 |
| Yock, PG | 2 |
| Honda, Y | 2 |
| Kandzari, DE | 2 |
| Leon, MB | 5 |
| Fitzgerald, PJ | 4 |
| Habara, S | 1 |
| Mitsudo, K | 2 |
| Kadota, K | 2 |
| Goto, T | 1 |
| Fujii, S | 1 |
| Yamamoto, H | 1 |
| Katoh, H | 1 |
| Oka, N | 1 |
| Fuku, Y | 1 |
| Hosogi, S | 1 |
| Hirono, A | 1 |
| Maruo, T | 1 |
| Tanaka, H | 1 |
| Shigemoto, Y | 1 |
| Hasegawa, D | 1 |
| Tasaka, H | 1 |
| Kusunose, M | 1 |
| Otsuru, S | 1 |
| Okamoto, Y | 1 |
| Saito, N | 1 |
| Tsujimoto, Y | 1 |
| Sethi, A | 1 |
| Bahekar, A | 1 |
| Bhuriya, R | 1 |
| Bajaj, A | 1 |
| Singh, PP | 1 |
| Arora, R | 1 |
| Khosla, S | 1 |
| New, G | 2 |
| Moses, JW | 3 |
| Roubin, GS | 2 |
| Colombo, A | 2 |
| Iyer, SS | 1 |
| Tio, FO | 1 |
| Mehran, R | 2 |
| Kipshidze, N | 2 |
| Babapulle, MN | 1 |
| Eisenberg, MJ | 1 |
| Kipshidze, NN | 1 |
| Iversen, P | 1 |
| Kim, HS | 1 |
| Yiazdi, H | 1 |
| Dangas, G | 1 |
| Seaborn, R | 1 |
| Tio, F | 1 |
| Waksman, R | 1 |
| Tsapenko, M | 1 |
| Stone, GW | 1 |
| Iyer, S | 1 |
| Iversen, PL | 1 |
| Hausleiter, J | 1 |
| Kastrati, A | 1 |
| Mehilli, J | 1 |
| Schühlen, H | 1 |
| Pache, J | 1 |
| Dotzer, F | 1 |
| Glatthor, C | 1 |
| Siebert, S | 1 |
| Dirschinger, J | 1 |
| Schömig, A | 1 |
| Shinozaki, N | 1 |
| Yokoi, H | 1 |
| Iwabuchi, M | 1 |
| Nosaka, H | 1 |
| Nobuyoshi, M | 1 |
| Lowe, R | 1 |
| Menown, IB | 1 |
| Nogareda, G | 1 |
| Penn, IM | 1 |
| Bakhai, A | 1 |
| Booth, J | 1 |
| Delahunty, N | 1 |
| Nugara, F | 1 |
| Clayton, T | 1 |
| McNeill, J | 1 |
| Davies, SW | 1 |
| Cumberland, DC | 2 |
| Stables, RH | 1 |
| Rodriguez, A | 1 |
| Rodríguez Alemparte, M | 1 |
| Fernández Pereira, C | 1 |
| Sampaolesi, A | 1 |
| da Rocha Loures Bueno, R | 1 |
| Vigo, F | 1 |
| Obregón, A | 1 |
| Palacios, IF | 1 |
| Airoldi, F | 1 |
| Di Mario, C | 1 |
| Ribichini, F | 1 |
| Presbitero, P | 1 |
| Sganzerla, P | 1 |
| Ferrero, V | 1 |
| Vassanelli, C | 1 |
| Briguori, C | 1 |
| Carlino, M | 1 |
| Montorfano, M | 1 |
| Biondi-Zoccai, GG | 1 |
| Chieffo, A | 1 |
| Ferrari, A | 1 |
| Fajadet, J | 2 |
| Wijns, W | 2 |
| Laarman, GJ | 1 |
| Kuck, KH | 1 |
| Ormiston, J | 1 |
| Münzel, T | 1 |
| Popma, JJ | 3 |
| Bonan, R | 1 |
| Kuntz, RE | 2 |
| Abizaid, A | 3 |
| Lansky, AJ | 1 |
| Tanajura, LF | 2 |
| Feres, F | 2 |
| Staico, R | 1 |
| Mattos, L | 1 |
| Chaves, A | 1 |
| Centemero, M | 1 |
| Sousa, AG | 1 |
| Sousa, JE | 1 |
| Zaugg, MJ | 1 |
| Schwartz, LB | 2 |
| Han, Y | 1 |
| Liang, M | 1 |
| Kang, J | 1 |
| Qi, Y | 1 |
| Deng, J | 1 |
| Xu, K | 1 |
| Yan, C | 1 |
| Fan, D | 1 |
| Jia, Z | 1 |
| Yan, X | 1 |
| Liu, X | 1 |
| Dong, W | 1 |
| Sun, F | 1 |
| Ji, J | 1 |
| Xu, J | 1 |
| Ren, K | 1 |
| Chen, W | 1 |
| Shen, J | 1 |
| Qiu, H | 1 |
| Gao, R | 1 |
| Hongo, Y | 1 |
| Yamasaki, M | 1 |
| Bonneau, HN | 1 |
| Cutlip, D | 1 |
| Zimetbaum, P | 1 |
| Hattori, K | 1 |
| Solberg, B | 1 |
| Larracas, C | 1 |
| Costa, Jde R | 1 |
| Zheng, H | 1 |
| Barragan, P | 1 |
| Corcos, T | 1 |
| Siméoni, JB | 1 |
| Favereau, X | 1 |
| Roquebert, PO | 1 |
| Guérin, Y | 1 |
| Sainsous, J | 1 |
| Grenadier, E | 1 |
| Roguin, A | 1 |
| Hertz, I | 1 |
| Peled, B | 1 |
| Boulos, M | 1 |
| Nikolsky, E | 1 |
| Amikam, S | 1 |
| Kerner, A | 1 |
| Cohen, S | 1 |
| Beyar, R | 1 |
| Armstrong, J | 1 |
| Gunn, J | 1 |
| Arnold, N | 1 |
| Malik, N | 1 |
| Chan, KH | 1 |
| Vick, T | 1 |
| Stratford, P | 1 |
| Holt, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions[NCT00217269] | 1,548 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| [NCT00973375] | 30 participants (Anticipated) | Observational | 2009-05-31 | Recruiting | |||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| A Prospective, Multi-Center, Non-Randomized, Single-Arm Trial to Evaluate the Safety and Feasibility of the TriMaxx Coronary Stent in de Novo Coronary Artery Lesions.[NCT00596661] | Phase 1 | 100 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for phosphorylcholine and Coronary Restenosis
| Article | Year |
|---|---|
Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
Topics: Coated Materials, Biocompatible; Confidence Intervals; Coronary Angiography; Coronary Restenosis; Dr | 2012 |
Coated stents for the prevention of restenosis: Part II.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Antineoplastic Agents; Clinical Trials as Topic; Coa | 2002 |
Local application of antisense for prevention of restenosis.
Topics: Angioplasty; Animals; Catheterization; Clinical Trials as Topic; Coronary Restenosis; Coronary Vesse | 2005 |
Coronary stents: in these days of climate change should all stents wear coats?
Topics: Carbon; Carbon Compounds, Inorganic; Chromium Alloys; Coronary Restenosis; Heparin; Humans; Metals; | 2005 |
Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent.
Topics: Anti-Inflammatory Agents; Blood Vessel Prosthesis Implantation; Clinical Trials as Topic; Coated Mat | 2006 |
10 trials available for phosphorylcholine and Coronary Restenosis
| Article | Year |
|---|---|
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Alloys; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible | 2009 |
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Alloys; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible | 2009 |
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Alloys; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible | 2009 |
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Alloys; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible | 2009 |
A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Re | 2004 |
Initial and follow-up results of the BiodivYsio phosphorylcholine coated stent for treatment of coronary artery disease.
Topics: Aged; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Reste | 2005 |
The SV stent study: a prospective, multicentre, angiographic evaluation of the BiodivYsio phosphorylcholine coated small vessel stent in small coronary vessels.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Cor | 2005 |
Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Cineangiography; Coated | 2005 |
17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Angiography; Coronary Dise | 2005 |
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial.
Topics: Aged; Australia; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Coronary Stenosis | 2007 |
Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; C | 2007 |
Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial).
Topics: Chromium Alloys; Coated Materials, Biocompatible; Cohort Studies; Coronary Artery Disease; Coronary | 2007 |
Stenting very small coronary narrowings (< 2 mm) using the biocompatible phosphorylcholine-coated coronary stent.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Artery Diseas | 2002 |
8 other studies available for phosphorylcholine and Coronary Restenosis
| Article | Year |
|---|---|
Serial clinical and angiographic follow-up after phosphorylcholine-coated stent implantation.
Topics: Aged; Aged, 80 and over; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Female; Hum | 2011 |
Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model.
Topics: Animals; Coated Materials, Biocompatible; Coronary Restenosis; Drug Delivery Systems; Endothelium, V | 2002 |
Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model.
Topics: Animals; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography | 2004 |
Estrogen-eluting stent implantation inhibits neointimal formation and extracellular signal-regulated kinase activation.
Topics: Analysis of Variance; Animals; Blotting, Western; Coated Materials, Biocompatible; Coronary Restenos | 2007 |
[Pilot study of a cell membrane like biomimetic drug-eluting coronary stent].
Topics: Angioplasty, Balloon, Coronary; Animals; Coated Materials, Biocompatible; Coronary Restenosis; Drug- | 2007 |
Clinical and angiographic results of percutaneous coronary revascularization using a trilayer stainless steel-tantalum-stainless steel phosphorylcholine-coated stent: the TriMaxx trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Brazil; Cardiovascular Agents; Cardiovascular Diseases; Corona | 2007 |
Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Blood Vesse | 1999 |
Angiopeptin-eluting stents: observations in human vessels and pig coronary arteries.
Topics: Animals; Cardiovascular Agents; Coated Materials, Biocompatible; Coronary Restenosis; Coronary Vesse | 2002 |